3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
4
Paraproteinemias
1
Amyloidosis
1
Alzheimer Disease
1
Interventions
Bortezomib
3
fludarabine
2
Tacrolimus
2
Cyclophosphamide
2
ofatumumab
1
fludarabine phosphate
1
daratumumab
1
birtamimab
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Vorinostat
1
Thalidomide
1
Stem Cell Transplantation
1
Plasma Exchange
1
Mycophenolic Acid
1
Melphalan
1
Lenalidomide
1
KW-2478
1
Hsp90 inhibitor KU757
1
Etoposide
1
Doxorubicin
1
Dexamethasone
1
Denosumab
1
Cisplatin
1
Calcium Dobesilate
1
Busulfan
1
Alemtuzumab
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Paraproteinemias
×
birtamimab
×
Clear all
NCT02632786
2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2
Completed
129 enrolled
18 charts